Over a short period of time, our society has seen a rapid increase in the interest and availability of cannabidiol (CBD) products and other products derived from cannabis. However, we still have a limited understanding of the safety profile of CBD and many other cannabis-derived compounds, including potential safety risks for people and animals. At the U.S. Food and Drug Administration, we see these knowledge gaps as an opportunity to develop new ways of building the science to inform public health decisions.
The FDA evaluates CBD just like any other substance we regulate, under a regulatory framework defined by law and with rigorous scientific evidence as a basis for both our regulatory approach and information we communicate. We’ve consistently communicated concerns and questions regarding the science, safety, and quality of many of these products based on currently available evidence. We still don’t have clear answers to important questions such as what adverse reactions may be associated with CBD products and what risks are associated with the long-term use of CBD products. Better data in these areas are needed for the FDA and other public health agencies to make informed, science-based decisions that impact public health. [Read more at FDA.gov]
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Notify me of follow-up comments by email.
Notify me of new posts by email.
Curaleaf, one of New York’s medical marijuana operators, has pulled tens of thousands of units of cannabis from dispensary shelves after the company switched to an unauthorized way of labeling potency that led patients to believe the marijuana they purchased was much stronger than usual. Curaleaf began displaying “dry weight” measurements on its products in July without…
Since 2012, 19 states, Washington, D.C., and Guam have legalized marijuana for recreational use — something 55% of Texans have said they either support or strongly support, according to a new Dallas Morning News-University of Texas at Tyler poll. And the numbers are even higher for medical use: 72% of those surveyed said they would either support or strongly…
Columbia attorney Dan Viets has promoted legalizing recreational marijuana for decades, and if his prediction and polls are correct, it could happen in November when voters statewide will cast ballots on the matter. “The data that we have from very recent independent polling is that 62% of Missouri voters approve it,” Viets said. “We’re not taking anything for granted,…
SEATTLE – The Washington State Liquor Cannabis Board is considering a point system that would give people convicted of a drug-related crime and did prison time – preferential treatment when applying for retail cannabis license. If adopted, the City of Seattle will adopt the same rules and set aside $1 million dollars in grant money…